Quadrant Biosciences to Offer Affordable Clarifi COVID-19 Testing to Businesses

Posted on September 15, 2021

SYRACUSE, NEW YORK, September 16, 2021 - Quadrant Biosciences Inc., a developer of molecular diagnostic tools, announced today that they will offer New York businesses with 100 or more employees affordable, weekly COVID testing to help meet new testing mandates that were announced by the federal government this week. 

The company’s Clarifi COVID-19 Test, developed in partnership with SUNY Upstate Medical University ("SUNY Upstate"), is a non-invasive, and easy to administer saliva swab test, and one of the few saliva tests to have received FDA emergency use authorization for pooled testing. Moreover, with a limit of detection (“LOD”) of as few as 600 copies of the SARS-CoV-2 virus per mL, the Clarifi COVID-19 test is the most sensitive saliva test currently on the market as referenced by the FDA.

The federal government recently announced that the Department of Labor’s Occupational Safety and Health Administration (OSHA) is developing a rule that will require all employers with 100 or more employees to ensure their workforce is fully vaccinated, or require any workers who remain unvaccinated to produce a weekly negative test result. 

To date, Quadrant’s Clarifi COVID-19 pooled testing program has been successfully adopted by numerous universities, K-12 schools, and government agencies. Recognizing that many private businesses across New York state, as well as the country, may need to quickly implement a testing program to satisfy this impending mandate, Quadrant is now offering its comprehensive and affordable testing solution to businesses. In addition to providing the test kits, the Clarifi COVID-19 testing program includes lab processing, result access via custom web app, training materials, and an account mentor to walk you through the onboarding process. 

The Clarifi COVID-19 Saliva Test is authorized for self-collection, so employers and employees can easily test on-site, with test results being delivered within 24-48 hours of samples arriving at Quadrant’s lab.  Employees, as well as designated “Organization Managers” for the company, will be able to quickly access results via an exclusive web app and make informed decisions should a positive case arise.

To learn more about COVID workplace testing, visit worksafe.quadrantbiosciences.com or request more information by completing a COVID request form

About Quadrant Biosciences

Quadrant Biosciences is a life science company developing molecular diagnostic solutions for large-scale health issues. The company has entered into collaborative research relationships with a number of institutions including SUNY Upstate Medical University and Penn State University to explore and develop novel biomarker technologies with a focus on Autism Spectrum Disorder, concussion, and Parkinson's disease. Recently, it has leveraged its expertise in RNA analysis to address the Covid-19 pandemic. Quadrant participates in the Start-up NY program, a New York State economic development program. For more information about Quadrant, please visit www.quadrantbiosciences.com.

The Clarifi COVID-19 Test Kit has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, and meet requirements to perform high-complexity tests. Clarifi COVID-19 has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Other Member News

Wicked
October 1, 2025

Wicked to Return to Landmark Theatre Dec. 3–14, 2025

Winner of over 100 international awards including the Grammy Award and three Tony Awards, WICKED has been performed in over 100 cities in 16 countries around the world.

new partners graphic
October 1, 2025

New Partners-CEO Insights October 2025

Please join us in welcoming new CenterState CEO Partner-level members.   

member news graphic
September 30, 2025

Member Essentials-CEO Insights October 2025

Below is a snapshot of the latest news and top headlines from our members. We want to hear from you!

new investors graphic
September 30, 2025

New Investors-CEO Insights October 2025

CenterState CEO wishes to recognize the members who have recently joined as Investors.

Harris Beach Murtha
September 30, 2025

36 Harris Beach Murtha Attorneys Selected to 2025 Upstate New York Super Lawyers® and Super Lawyers: Rising Stars® Lists

Super Lawyers is a nationally recognized professional survey and ranking service of accomplished attorneys who have achieved a high degree of peer recognition and professional achievement in more than 70 practice areas.

Mitch Nelson, Technician of the Year
September 30, 2025

Eastern Security Services Technician Receives National Distinction

The award highlights excellence in system design, installation, and maintenance while honoring the vital role technicians play in protecting people and property.

ambassadors sfcu graphic
September 30, 2025

Ambassadors-CEO Insights October 2025

Presented by SFCU

Dan and Andrea
September 29, 2025

FMF&E CPA, P.C. Announces New Managing Partner and Key Leadership Appointments

As the Firm celebrates its 45th year in business, this transition marks a significant milestone in the Firm’s continued growth and evolution.

KELLI ARNOLD NAMED CHIEF STRATEGY AND GROWTH OFFICER AT M3 PLACEMENT AND PARTNERSHIP
September 29, 2025

Kelli Arnold Named Chief Strategy and Growth Officer at M3 Placement and Partnership

Veteran banking executive to spearhead firm’s expansion into new markets and services.